Monday , February 24 2020

Samsung Bioepis applied for SB8 USA

Panoramic view of Samsung Bioepi's office building. Samsung Bioepis has started reviewing documents for Biologics License Application (BLA) from SB8 (Avastin Biosimilar, ingredient name Bevacizumab) at the Food and Drug Administration (FDA). …

Read More »

Samsung Bioepis applied for SB8 USA

Panoramic view of Samsung Bioepi's office building. Samsung Bioepis has started reviewing documents for Biologics License Application (BLA) from SB8 (Avastin Biosimilar, ingredient name Bevacizumab) at the Food and Drug Administration (FDA). …

Read More »